Get intelligentvalue.com

Own it today or select a payment plan

Secured by Stripe

Premium Domain Name

intelligentvalue.com

intelligentvalue.com logo

is available for purchase

51 views
Visitors fromUSUS 54%·AUAU 32%·ININ 7%·GBGB 2%·FRFR 2%

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

VisaMastercardAmerican ExpressDiscoverDiners ClubJCBApple PayGoogle Pay

Gamida Cell to Report Second Quarter 2023 Financial Results

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Conference Call and Webcast Scheduled for Monday, August 14th at 8:30 am Eastern Time

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the second quarter ended June 30, 2023 on Monday, August 14, 2023.

Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates and answer questions.

To access the conference call by phone, please register here and be advised to do so at least 10 minutes prior to joining. A live webcast of the conference call can be accessed by computer in the “Investors & Media” section of the Gamida Cell website at www.gamida-cell.com. A replay of the webcast will be available approximately two hours after the event, for approximately 30 days.

About Gamida Cell

Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. The company’s proprietary nicotinamide (NAM) technology leverages the properties of NAM to enhance and expand cells, creating allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies. These include Omisirge®, an FDA-approved nicotinamide modified allogeneic hematopoietic progenitor cell therapy, and GDA-201, an NK cell therapy candidate being investigated for the treatment of hematologic malignancies. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, Twitter, Facebook or Instagram.

Omisirge® is a registered trademark of Gamida Cell Inc. © 2023 Gamida Cell Inc. All Rights Reserved.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  271.58
+36.08 (15.32%)
AAPL  308.91
-24.52 (-7.35%)
AMD  476.15
-9.24 (-1.90%)
BAC  61.95
+0.22 (0.36%)
GOOG  356.65
+22.97 (6.88%)
META  556.71
+17.68 (3.28%)
MSFT  464.72
+13.62 (3.02%)
NVDA  200.75
+5.71 (2.93%)
ORCL  129.87
+2.31 (1.81%)
TSLA  311.21
+2.36 (0.76%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.